Study on Tazemetostat with Rituximab and Bendamustine for Initial Treatment of High Tumor Burden Follicular Lymphoma

Inclusion Criteria

• Must provide written consent and authorization for the release of personal health information.
• Must be 18 years or older.
• Must have a performance status score of 0-2, indicating full activity or some restriction in strenuous activities.
• Must have low-grade follicular lymphoma (grade 1-2 or 3A) without evidence of transformed lymphoma.
• Must have stage II, III, or IV lymphoma.
• Must meet criteria for high tumor burden follicular lymphoma or be high risk according to specific guidelines.
• Must have at least one tumor site that can be measured by scans.
• Must not have received prior therapy except for limited radiation, single-agent rituximab, or steroids for symptom control.
• Must have prior EZH2 testing or be willing to provide tissue for testing.
• Must have adequate organ function based on specific blood tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during and after the study.
• Men must agree to use effective contraception during and after the study.
• Must be able to understand and comply with study procedures.

Exclusion Criteria

• Active infection requiring treatment within 4 weeks of starting the study.
• Pregnant or breastfeeding women.
• Have another cancer within the last 3 years, except for certain non-threatening cancers.
• Have active cancer spread to the brain or spinal fluid.
• Have taken any investigational drug within 4 weeks before starting the study.
• Require chronic use of certain medications that affect drug metabolism.
• Have significant infections requiring treatment.
• Have uncontrolled HIV infection.
• Have hepatitis C infection unless specific tests are negative.
• Must be tested for hepatitis B and meet specific criteria to participate.
• Have significant heart disease or recent heart attack or chest pain.